Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics ...
Eli Lilly has a Fever, and the only prescription is a new corporate partnership. | Eli Lilly has a Fever, and the only ...
During the Q&A portion of Amgen’s quarterly conference call Thursday, eight of the first nine questions were about the ...
Just about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the ...
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with ...
While not one of the largest biopharma deals of the year so far—a crown currently worn by Gilead’s $4.43 billion acquisition ...
As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a ...
The FTC’s second request imposes an additional waiting period of up to 30 days for the agency to review the deal from the time the Novo Nordisk Foundation and Catalent submit the required information.
Even with the threat of a potential new competitor in the respiratory syncytial virus (RSV) vaccine race on the horizon, GSK ...
With its newly launched predictive analytics platform, Real Chemistry is hoping to “shine a light” on the GLP-1 agonist ...
Moderna has launched a new video series to energize its social media followers’ midafternoon breaks. | No 2 p.m. slump ...
With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results